The newly developed high-throughput “ACTH AlphaLISA assay” led to the identification a dual PI3K/HDAC inhibitor, CUDC-907, as a potential targeted therapy for ACTHomas. This evidence concerns the gene HDAC9 and ACTH-producing pituitary gland adenoma.